Alnylam Pharmaceuticals, Inc.

Hello, ladies and gentlemen. Thank you for standing by and welcome to the Alnylam Pharmaceuticals Q3 2021 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you need to press star 1 on your telephone. If you require any further assistance, please press star 0. I would now like to turn the call over to the company who may begin.

Good morning. I'm Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at Alnylam. With me today on the phone are John Maragonori, Chief Executive Officer of Tolga Tangular, Chief Commercial Officer, Akshay Vaishnav, President of R&D, Jeff Poulton, Chief Financial Officer, and Yvonne Greenstreet, President and Chief Operating Officer. For those of you participating via conference call, the accompanying slides can be accessed by going to the events section of the investors page of our website, investors.alnylam.com slash events. During today's call, as outlined in slide two, John will provide some introductory remarks, provide some general context, and discuss the planned leadership transition. Yvonne will provide some remarks on the leadership transition plans. Togo will provide an update on our global commercial progress. Akshay will review recent clinical and preclinical updates, including the new positive top-line results of the 18-month endpoints of the Helios-A study of Butresaran. Jeff will review our financials and then provide a brief summary of upcoming milestones before opening the call to your questions. I would like to remind you that this call contains remarks concerning ILM's future expectations, plans, and prospects, which constitute forward-looking statements for the purposes of the Safe Harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recently quarterly report on file with the SEC. In addition, any forward-looking statements represent our views only as to the date of this recording and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update such statements. With that, I will turn the call over to John.

Thanks, Christine, and thank you, everyone, for joining the call today. In the third quarter and recent period, we made continued progress bringing our commercial RNAi therapeutics to patients around the world, We advanced our clinical pipeline of over a dozen potential transformative medicine programs, and we delivered on the promise of sustainable innovation with R&AI, with our industry-leading platform and our preclinical efforts. Of course, a highlight for the period was the positive top-line 18-month results from the Heli-OSA phase 3 study of Butrisaran that we announced just yesterday. And Akshay will review those results very shortly. As we announced this morning, after much thoughtful consideration and planning, I've decided that this is the right time to begin a smooth transition of leadership at El Nilo. I've decided that this is the time for me to begin a new chapter in my career of yet again pushing the bounds of biomedical innovation by helping entrepreneurs and companies advance new modalities to improve the lives of patients. I couldn't be more pleased that Yvonne Green Street has agreed to help lead El Nile in a planned transition that will occur at the end of this year. Of course, I am so honored to have had the opportunity to build El Nile over the last 19 years, bringing RNA therapeutics to patients around the world. I am so proud of what we've accomplished, and I'm so thankful for the opportunity to have worked with our past and present Alnylam team to build this incredibly special company. I have no doubt that Alnylam will continue to soar in the years to come, helping patients with its transformative science and medicines. So with that, let me turn it over to Yvonne to make some remarks as well. Yvonne?